EPISODE · Oct 31, 2025 · 18 MIN
Merck Third Quarter 2025 Sales and Earnings
from Daily Market Download · host Daily Market Download
The provided text consists of excerpts from a Merck & Co., Inc. Third-Quarter 2025 Sales and Earnings conference call presentation, outlining the company's performance, strategy, and pipeline updates. The presentation highlights $17.3 billion in worldwide sales for the quarter, driven by strong growth in Oncology, particularly KEYTRUDA ($8.1 billion in sales), and Animal Health. Management discusses the company's focus on innovation and growth, citing a pipeline with around 80 Phase 3 trials and a strategic acquisition, Verona Pharma, for a new COPD treatment. The report also details progress across various therapeutic areas, including Immunology, Ophthalmology, and Cardiopulmonary diseases, along with an updated 2025 financial outlook predicting non-GAAP EPS between $8.93 and $8.98.
What this episode covers
The provided text consists of excerpts from a Merck & Co., Inc. Third-Quarter 2025 Sales and Earnings conference call presentation, outlining the company's performance, strategy, and pipeline updates. The presentation highlights $17.3 billion in worldwide sales for the quarter, driven by strong growth in Oncology, particularly KEYTRUDA ($8.1 billion in sales), and Animal Health. Management discusses the company's focus on innovation and growth, citing a pipeline with around 80 Phase 3 trials and a strategic acquisition, Verona Pharma, for a new COPD treatment. The report also details progress across various therapeutic areas, including Immunology, Ophthalmology, and Cardiopulmonary diseases, along with an updated 2025 financial outlook predicting non-GAAP EPS between $8.93 and $8.98.
NOW PLAYING
Merck Third Quarter 2025 Sales and Earnings
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m